Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic MelanomaRenáta Váraljai, Alexander Roesch, Felix C. E. Vogel et al.|JCO Precision Oncology|2019Cited by 54
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with PembrolizumabGil Awada, Bart Neyns, Yanina Jansen et al.|Cancers|2021Cited by 36
Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumabGil Awada, Bart Neyns, İsa Aykut Özdemir et al.|Annals of Oncology|2018Cited by 4
Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy.Gil Awada, Bart Neyns, Julia Katharina Schwarze et al.|Journal of Clinical Oncology|2020Cited by 3
ctDNA as a noninvasive monitoring tool in metastatic melanoma.Renáta Váraljai, Alexander Roesch, Kilian Wistuba‐Hamprecht et al.|Journal of Clinical Oncology|2019Cited by 0